MEDINET Japan and Stempeutics India Sign Licensing Deal for Stempeucel

• MEDINET Japan and Stempeutics India sign option license agreement for Stempeucel
• Deal enables potential exclusive rights to develop and commercialize the therapy in Japan
• Stempeucel aims to treat Chronic Limb Threatening Ischemia (CLTI), offering hope to patients

MEDINET Japan has signed an option license agreement with Stempeutics India, a Manipal Group company, to develop and commercialize Stempeucel, a cell-based therapy, in Japan. The agreement covers the Japanese market for treating Chronic Limb Threatening Ischemia (CLTI), a severe form of peripheral arterial disease.

Under the deal, MEDINET can exercise its option to obtain exclusive rights for Stempeucel’s development and commercialization in Japan, following local regulatory approval from the Pharmaceuticals and Medical Devices Agency (PMDA). Stempeutics will receive upfront and milestone payments, along with royalties upon product commercialization. The product will be manufactured at Stempeutics’ cGMP facility in Bengaluru and shipped to Japan for clinical trials and commercial use.

Stempeucel is an innovative therapy developed using pooled bone marrow-derived Mesenchymal Stromal Cells (MSCs) from healthy donors. This proprietary process enhances the cells’ ability to reduce inflammation, promote new blood vessel formation, and restore blood flow in affected tissues, offering a breakthrough solution for CLTI patients at risk of limb amputation.

Also Read: IIT Delhi Partners with KVS to Boost STEM Learning for School Students

Leaders from both companies hailed the partnership as a historic milestone for regenerative medicine in Asia. They emphasized that the therapy, already approved and used to treat over 600 patients in India, could soon offer relief to Japanese patients suffering from CLTI.

Read More News :

10 Stocks Likely to Outshine the Market Today

Amit Shah Unveils Vision To Make India A Global Maritime Powerhouse